Stock-research Ratings: Agile Therapeutics, Inc. (AGRX), Arcadia Biosciences, Inc. (RKDA)

Agile Therapeutics, Inc. (NASDAQ:AGRX) tinted gains of +12.12% (+0.12 points) to US$1.11. The volume of 2.64 Million shares climbed down over an trading activity of 367.74 Million shares. EPS ratio determined by looking at last 12 month figures is -0.65. Over the same time span, the stock marked US$3.92 as its best level and the lowest price reached was US$0.23. The corporation has a market cap of US$34.03 Million.

Agile Therapeutics, Inc. (NASDAQ:AGRX)’s earnings per share has been growing at a 11.8 percent rate over the past 5 year when average revenue increase was noted as 0 percent. The return on equity ratio or ROE stands at -76.3 percent while most common profitability ratio return on investment (ROI) was 0 percent. The company’s institutional ownership is monitored at 44 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 0 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 2 think it is Hold. Recently, analysts have updated the overall rating to 2.33. 4 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Arcadia Biosciences, Inc. (NASDAQ:RKDA) is worth US$21.82 Million and has recently risen 14.12% to US$5.01. The latest exchange of 1.7 Million shares is below its average trading activity of 107.27 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$66.56 while the mean 12-month price target for the shares is US$20.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 1.62, and a price to sales ratio of 9.09. For the past 5 years, the company’s revenue has grown -10.5%, while the company’s earnings per share has grown -4.9%. With an institutional ownership near 8.1%, it carries an earnings per share ratio of -7.33.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 1 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.